Medical Design and Outsourcing

  • Home
  • Medical Device Business
    • Mergers & Acquisitions
    • Financial
    • Regulatory
  • Applications
    • Cardiovascular
    • Devices
    • Imaging
    • Implantables
    • Medical Equipment
    • Orthopedic
    • Surgical
  • Technologies
    • Contract Manufacturing
    • Components
    • Electronics
    • Extrusions
    • Materials
    • Motion Control
    • Prototyping
    • Pumps
    • Tubing
  • Med Tech Resources
    • DeviceTalks Tuesdays
    • Digital Editions
    • eBooks
    • Manufacturer Search
    • Medical Device Handbook
    • MedTech 100 Index
    • Podcasts
    • Print Subscription
    • The Big 100
    • Webinars / Digital Events
    • Whitepapers
    • Video
  • 2022 Leadership in MedTech
    • 2022 Leadership Voting!
    • 2021 Winners
    • 2020 Winners
  • Women in Medtech

Recent Study Shows Leukotheraâ„¢ Combined with Other Agents Has Enhanced Anti-Leukemia Effects

June 27, 2011 By Bio-Medicine.Org

NEW BRUNSWICK, N.J., June 27, 2011 /PRNewswire/ — Recent
findings published in the scientific journal Leukemia
Research
(
http://www.sciencedirect.com/science/article/pii/S0145212611002505),
showed that when combined with standard anti-leukemia agents, the
biological activity of LeukotheraTM, a drug candidate
under development by Actinobac Biomed, Inc., showed synergistic
anti-leukemia effects.

The outcome of these in vitro experiments
demonstrated that combining LeukotheraTM with
such widely employed drugs as etoposide, mitoxantrone,
daunorubicin, busulfan and imatinib killed leukemia cells much more
effectively than when the agents were used alone.
 LeukotheraTM is a natural biologic agent that
specifically targets malignant and/or inflammatory white blood
cells involved in disease.  

Dr. Scott Kachlany, founder of Actinobac Biomed, explained.
“Drug combination therapies for cancer are now frequently
considered by oncologists due to their many advantages, which
include the possibility of reducing doses of toxic chemotherapeutic
agents and a lower chance of developing drug resistance,” he said.
 “The biological mechanism of LeukotheraTM differs
from that of other cancer drugs so including it to blood cancer
treatment protocols may be a highly effective strategy.”

Actinobac Biomed, Inc. was founded in 2009 with financial
backing from Foundation Venture Capital Group, LLC, to develop
commercial products based upon technology developed at the
University of Medicine and Dentistry of New Jersey.  The
company has exclusively licensed the rights to develop
LeukotheraTM as a therapeutic agent for the treatment of
hematologic malignancies, autoimmune and inflammatory diseases and
HIV infection.

“We provided early seed funding to Actinobac because we are
convinced that

‘/>”/>

SOURCE

Related Articles Read More >

A portrait of ResMed President and COO Rob Douglas
ResMed finds a solution to semiconductor shortage, as well as some humor in it
Johnson & Johnson Office of Digital Innovation Leader Peter Schulam
Imagining the future of cloud-connected medical devices with Johnson & Johnson leaders
Withings Body Scan
Withings plans launch for Body Scan smart scale platform
BinaxNow COVID-19 Ag Card
Time recognizes Abbott offerings among this year’s 100 best inventions

DeviceTalks Weekly.

July 1, 2022
Boston Scientific CEO Mike Mahoney on building a corporate culture that drives high growth results
See More >

MDO Digital Edition

Digital Edition

Subscribe to Medical Design & Outsourcing. Bookmark, share and interact with the leading medical design engineering magazine today.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
DeviceTalks

DeviceTalks is a conversation among medical technology leaders. It's events, podcasts, webinars and one-on-one exchanges of ideas & insights.

DeviceTalks

New MedTech Resource

Medical Tubing

Enewsletter Subscriptions

Enewsletter Subscriptions

MassDevice

Mass Device

The Medical Device Business Journal. MassDevice is the leading medical device news business journal telling the stories of the devices that save lives.

Visit Website
MDO ad
Medical Design and Outsourcing
  • MassDevice
  • DeviceTalks
  • MedTech 100 Index
  • Medical Tubing + Extrusion
  • Drug Delivery Business News
  • Drug Discovery & Development
  • Pharmaceutical Processing World
  • R&D World
  • About Us/Contact
  • Advertise With Us
  • Subscribe to Print Magazine
  • Subscribe to E-newsletter
  • Attend our Monthly Webinars
  • Listen to our Weekly Podcasts
  • Join our DeviceTalks Tuesdays Discussion

Copyright © 2022 WTWH Media, LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media LLC. Site Map | Privacy Policy | RSS

Search Medical Design & Outsourcing

  • Home
  • Medical Device Business
    • Mergers & Acquisitions
    • Financial
    • Regulatory
  • Applications
    • Cardiovascular
    • Devices
    • Imaging
    • Implantables
    • Medical Equipment
    • Orthopedic
    • Surgical
  • Technologies
    • Contract Manufacturing
    • Components
    • Electronics
    • Extrusions
    • Materials
    • Motion Control
    • Prototyping
    • Pumps
    • Tubing
  • Med Tech Resources
    • DeviceTalks Tuesdays
    • Digital Editions
    • eBooks
    • Manufacturer Search
    • Medical Device Handbook
    • MedTech 100 Index
    • Podcasts
    • Print Subscription
    • The Big 100
    • Webinars / Digital Events
    • Whitepapers
    • Video
  • 2022 Leadership in MedTech
    • 2022 Leadership Voting!
    • 2021 Winners
    • 2020 Winners
  • Women in Medtech